RxDoctor Payments Data

Charles Kaiser, MD

Ophthalmology · Miami, FLNPI 1801859962

Payments from drug & device makers

$15,519in general payments, 2019–2025

Across 568 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$2K
  • Bausch & Lomb Americas Inc.$1K
  • NEW World Medical,inc.$1K
  • Mallinckrodt Hospital Products Inc.$928
  • Oyster Point Pharma, Inc.$890
  • plus $7K from 33 others

What the payments were for

  • Food & beverage$15,42299%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,519 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$212,566
Medicare patients
771
Services billed
1,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine104$119,007
LumiganBimatoprost115$72,019
EysuvisLoteprednol Etabonate82$40,674
XdemvyLotilaner21$39,414
VyzultaLatanoprostene Bunod71$38,836
Fluorometholone523$30,928
XiidraLifitegrast12$20,952
CombiganBrimonidine Tartrate/Timolol37$17,955
MieboPerfluorohexyloctane/Pf20$14,581
RocklatanNetarsudil Mesylat/Latanoprost32$14,565
SimbrinzaBrinzolamide/Brimonidine Tart33$7,650
Prednisolone Acetate209$6,974
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$5,775
RhopressaNetarsudil Mesylate16$5,630
Latanoprost383$4,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$1,829$208,981256 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$1,349$74,369103 claims
Kala Pharmaceuticals, Inc.Eysuvis$342$40,67482 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$381$39,41421 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$246$20,19448 claims
AlconSimbrinza$2,185$7,65033 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$328$2,22013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →